Search Results

Synchron , the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the launch of a community-centered BCI registry to bring patients, carers and clinicians together to learn how BCI is being designed to provide benefit to people with limited mobility.

Synchron today announced the acquisition of an equity stake in ACQUANDAS, a leading technology provider specializing in state-of-the-art high-precision components for the healthcare industry and other industries.

Synchron today announced the appointment of Riki Banerjee, Ph.D., to Chief Technology Officer (CTO).

Alimera Sciences, Inc. announces that it has completed enrollment for the company’s Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ in the treatment of chronic non-infectious uveitis and related intraocular inflammation.

Synchron, the endovascular brain-computer interface company developing technology designed to restore functionality in patients with motor impairment, announced the appointment of Andy Rasdal to its Board of Directors.

Synchron, the endovascular brain-computer interface company developing technology to restore functionality in patients with severe paralysis, announced completion of patient enrollment in the US-based COMMAND trial.

Synchron, an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device.

Synchron today announced the COMMAND trial is commencing at Gates Vascular Institute, a Kaleida Health facility in Buffalo, N.Y. and teaching affiliate of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB).